Dr Reed on the Investigation of Trastuzumab Deruxtecan in HER2+ Osteosarcoma

Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.

Related Keywords

Damonr Reed , ,Department Of Individualized Cancer Management ,Young Adult Program ,Moffitt Cancer Center ,Individualized Cancer Management ,Young Adult ,Adolescent Young Adult Program ,Evolutionary Therapy ,Onclive Tv ,Sarcoma ,